Adrenal Crisis Management Market
Adrenal Crisis Management Market Forecasts to 2032 – Global Analysis By Treatment Type (Glucocorticoid Therapy, Mineralocorticoid Therapy, Fluid & Electrolyte Replacement Therapy and Adjunctive Therapies), Route of Administration (Intravenous, Intramuscular, Oral and Subcutaneous), Patient Group, Distribution Channel, End User and By Geography
According to Stratistics MRC, the Global Adrenal Crisis Management Market is accounted for $2.6 billion in 2025 and is expected to reach $4.4 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Adrenal crisis management involves the immediate administration of intravenous or intramuscular hydrocortisone, followed by rapid fluid resuscitation using isotonic saline. It is a critical protocol for patients with adrenal insufficiency facing acute stressors such as infection, trauma, or surgery. Timely intervention prevents shock, organ failure, and death. Continued hydrocortisone dosing and endocrinologist oversight are essential until full clinical recovery is achieved.
According to the National Institutes of Health (NIH), adrenal insufficiency, the primary risk factor for adrenal crisis, has a prevalence of approximately 110-144 cases per million population.
Market Dynamics:
Driver:
Rising prevalence of autoimmune disorders
The escalating incidence of autoimmune conditions such as Addison's disease, congenital adrenal hyperplasia, and primary adrenal insufficiency significantly drives the adrenal crisis management market expansion. Improved diagnostic capabilities and enhanced awareness among healthcare professionals contribute to earlier detection rates. The growing geriatric population, particularly susceptible to endocrine disorders, further amplifies market demand. Moreover, lifestyle factors, including chronic stress, environmental toxins, and dietary changes, have been linked to increased autoimmune disorder prevalence. This epidemiological trend necessitates robust therapeutic interventions and emergency management protocols, thereby creating substantial market opportunities for pharmaceutical companies and medical device manufacturers specializing in adrenal crisis prevention and treatment solutions.
Restraint:
High cost of treatment
Emergency hydrocortisone injections, continuous hormone replacement therapy, and specialized monitoring equipment require considerable healthcare expenditure. The chronic nature of adrenal insufficiency demands lifelong treatment regimens, creating cumulative cost pressures for patients and healthcare systems. Moreover, limited insurance coverage for certain therapeutic options and diagnostic procedures exacerbates affordability challenges. The economic strain is particularly pronounced in developing regions where healthcare infrastructure and reimbursement policies remain inadequate, potentially limiting market penetration and adoption of advanced adrenal crisis management solutions across diverse patient populations.
Opportunity:
Digital health solutions for patient monitoring and adherence
Wearable devices equipped with cortisol monitoring capabilities enable real-time physiological tracking, facilitating proactive crisis prevention. Smartphone applications provide medication reminders, stress level monitoring, and emergency response protocols, improving patient outcomes. Telemedicine platforms connect patients with endocrinologists for remote consultations and dosage adjustments. Moreover, artificial intelligence algorithms can predict crisis episodes based on patient data patterns, enabling preventive interventions. The COVID-19 pandemic has accelerated digital health adoption, creating favorable market conditions for innovative monitoring solutions that enhance patient safety while reducing healthcare costs and hospital readmissions.
Threat:
Reimbursement hurdles for newer products and kits
Regulatory agencies require extensive clinical evidence demonstrating cost-effectiveness and safety profiles before approving coverage. Insurance providers often prioritize established treatments over innovative solutions, limiting access to advanced therapeutic options. The lengthy reimbursement approval timeline delays product commercialization and market entry strategies. Moreover, varying reimbursement policies across different regions and healthcare systems complicate global market penetration efforts. These challenges particularly affect emergency injection devices and novel diagnostic kits, potentially hindering innovation adoption and restricting patient access to cutting-edge adrenal crisis management technologies despite their clinical benefits.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the adrenal crisis management market through disrupted healthcare services and delayed routine monitoring appointments. Patients with adrenal insufficiency faced increased infection vulnerability, necessitating enhanced precautionary measures and stress-dose steroid protocols. Additionally, supply chain disruptions affected medication availability, particularly hydrocortisone products. Telemedicine adoption surged as healthcare providers sought alternative consultation methods, accelerating digital health solution integration. Moreover, the pandemic highlighted the importance of emergency preparedness, driving demand for home-based monitoring devices and self-administration kits for crisis management.
The glucocorticoid therapy segment is expected to be the largest during the forecast period
The glucocorticoid therapy segment is expected to account for the largest market share during the forecast period due to its fundamental role as the primary treatment modality for adrenal insufficiency and crisis prevention. Hydrocortisone remains the gold standard for hormone replacement therapy, with extensive clinical evidence supporting its efficacy and safety profile. Additionally, the segment encompasses various formulations, including oral tablets, injectable solutions, and emergency auto-injectors, catering to diverse patient needs. The well-established treatment protocols and physician familiarity with glucocorticoid administration contribute to sustained market leadership.
The paediatrics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the pediatrics segment is predicted to witness the highest growth rate due to increasing recognition and diagnosis of congenital adrenal disorders in children. Early-onset conditions such as congenital adrenal hyperplasia and primary adrenal insufficiency require specialized treatment approaches tailored to pediatric physiology. Additionally, improved neonatal screening programs enable earlier detection, driving demand for age-appropriate therapeutic formulations and monitoring devices. The segment benefits from enhanced awareness among pediatric endocrinologists and primary care physicians regarding adrenal crisis recognition. Moreover, growing parental awareness and advocacy for comprehensive pediatric adrenal care further accelerates segment expansion.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share through advanced healthcare infrastructure, comprehensive insurance coverage, and robust pharmaceutical research capabilities. The region benefits from established endocrinology treatment centers and specialized adrenal insufficiency clinics providing expert patient care. Additionally, strong regulatory frameworks ensure product quality and safety while facilitating innovation adoption. High healthcare expenditure and patient awareness levels support premium treatment options and advanced monitoring technologies. Government initiatives promoting rare disease research and patient advocacy organizations contribute to sustained market growth.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure, increasing diagnostic capabilities, and rising disease awareness among healthcare professionals. Growing economic prosperity enables enhanced healthcare spending and access to advanced therapeutic options. Additionally, government initiatives promoting healthcare accessibility and insurance coverage expansion facilitate market penetration. The region benefits from a large patient population and improving epidemiological surveillance systems for endocrine disorders. Rising physician training programs in endocrinology and emergency medicine enhance crisis recognition and management capabilities. The digital health technology adoption and telemedicine integration further support rapid market expansion across diverse Asia Pacific healthcare systems.
Key players in the market
Some of the key players in Adrenal Crisis Management Market include Eton Pharmaceuticals, Takeda, Pfizer, Antares Pharma, Sandoz, Halozyme, Novartis, Teva, GSK, AbbVie, Mylan, Ferring, Hikma, Sun Pharma, Cipla, Sanofi, Bayer, AstraZeneca, Amneal, and Endo International.
Key Developments:
In July 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe form and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
In January 2022, Antares Pharma, Inc. a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.
In June 2021, Eton Pharmaceuticals, Inc the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.
Treatment Types Covered:
• Glucocorticoid Therapy
• Mineralocorticoid Therapy (Fludrocortisone)
• Fluid & Electrolyte Replacement Therapy
• Adjunctive Therapies
Route of Administrations:
• Intravenous (IV)
• Intramuscular (IM)
• Oral
• Subcutaneous
Patient Groups Covered:
• Adults
• Pediatrics
• Geriatrics
• Neonates
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Drug Distributors
End Users Covered:
• Hospitals
• Emergency Care Centers
• Specialty Clinics
• Home Care Settings
• Ambulatory Surgical Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Adrenal Crisis Management Market, By Treatment Type
5.1 Introduction
5.2 Glucocorticoid Therapy
5.2.1 Hydrocortisone (IV/IM)
5.2.2 Dexamethasone
5.2.3 Other Glucocorticoids
5.3 Mineralocorticoid Therapy (Fludrocortisone)
5.4 Fluid & Electrolyte Replacement Therapy
5.5 Adjunctive Therapies
6 Global Adrenal Crisis Management Market, By Route of Administration
6.1 Introduction
6.2 Intravenous (IV)
6.3 Intramuscular (IM)
6.4 Oral
6.5 Subcutaneous
7 Global Adrenal Crisis Management Market, By Patient Group
7.1 Introduction
7.2 Adults
7.3 Pediatrics
7.4 Geriatrics
7.5 Neonates
8 Global Adrenal Crisis Management Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Specialty Drug Distributors
9 Global Adrenal Crisis Management Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Emergency Care Centers
9.4 Specialty Clinics
9.5 Home Care Settings
9.6 Ambulatory Surgical Centers
9.7 Other End Users
10 Global Adrenal Crisis Management Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Eton Pharmaceuticals
12.2 Takeda Pharmaceutical Company Limited
12.3 Pfizer Inc.
12.4 Antares Pharma
12.5 Sandoz International GmbH
12.6 Halozyme Therapeutics
12.7 Novartis AG
12.8 Teva Pharmaceutical Industries Ltd.
12.9 GlaxoSmithKline plc
12.10 AbbVie Inc.
12.11 Mylan N.V.
12.12 Ferring Pharmaceuticals
12.13 Hikma Pharmaceuticals
12.14 Sun Pharmaceutical Industries Ltd.
12.15 Cipla Ltd.
12.16 Sanofi S.A.
12.17 Bayer AG
12.18 AstraZeneca plc
12.19 Amneal Pharmaceuticals
12.20 Endo International plc
List of Tables
1 Global Adrenal Crisis Management Market Outlook, By Region (2024-2032) ($MN)
2 Global Adrenal Crisis Management Market Outlook, By Treatment Type (2024-2032) ($MN)
3 Global Adrenal Crisis Management Market Outlook, By Glucocorticoid Therapy (2024-2032) ($MN)
4 Global Adrenal Crisis Management Market Outlook, By Hydrocortisone (IV/IM) (2024-2032) ($MN)
5 Global Adrenal Crisis Management Market Outlook, By Dexamethasone (2024-2032) ($MN)
6 Global Adrenal Crisis Management Market Outlook, By Other Glucocorticoids (2024-2032) ($MN)
7 Global Adrenal Crisis Management Market Outlook, By Mineralocorticoid Therapy (Fludrocortisone) (2024-2032) ($MN)
8 Global Adrenal Crisis Management Market Outlook, By Fluid & Electrolyte Replacement Therapy (2024-2032) ($MN)
9 Global Adrenal Crisis Management Market Outlook, By Adjunctive Therapies (2024-2032) ($MN)
10 Global Adrenal Crisis Management Market Outlook, By Route of Administration (2024-2032) ($MN)
11 Global Adrenal Crisis Management Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
12 Global Adrenal Crisis Management Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
13 Global Adrenal Crisis Management Market Outlook, By Oral (2024-2032) ($MN)
14 Global Adrenal Crisis Management Market Outlook, By Subcutaneous (2024-2032) ($MN)
15 Global Adrenal Crisis Management Market Outlook, By Patient Group (2024-2032) ($MN)
16 Global Adrenal Crisis Management Market Outlook, By Adults (2024-2032) ($MN)
17 Global Adrenal Crisis Management Market Outlook, By Pediatrics (2024-2032) ($MN)
18 Global Adrenal Crisis Management Market Outlook, By Geriatrics (2024-2032) ($MN)
19 Global Adrenal Crisis Management Market Outlook, By Neonates (2024-2032) ($MN)
20 Global Adrenal Crisis Management Market Outlook, By Distribution Channel (2024-2032) ($MN)
21 Global Adrenal Crisis Management Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
22 Global Adrenal Crisis Management Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
23 Global Adrenal Crisis Management Market Outlook, By Online Pharmacies (2024-2032) ($MN)
24 Global Adrenal Crisis Management Market Outlook, By Specialty Drug Distributors (2024-2032) ($MN)
25 Global Adrenal Crisis Management Market Outlook, By End User (2024-2032) ($MN)
26 Global Adrenal Crisis Management Market Outlook, By Hospitals (2024-2032) ($MN)
27 Global Adrenal Crisis Management Market Outlook, By Emergency Care Centers (2024-2032) ($MN)
28 Global Adrenal Crisis Management Market Outlook, By Specialty Clinics (2024-2032) ($MN)
29 Global Adrenal Crisis Management Market Outlook, By Home Care Settings (2024-2032) ($MN)
30 Global Adrenal Crisis Management Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
31 Global Adrenal Crisis Management Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
